Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities

Clin Pharmacol Ther. 1982 Feb;31(2):184-6. doi: 10.1038/clpt.1982.29.

Abstract

Thirty-eight healthy subjects were given single oral doses of debrisoquine and sparteine in a crossover study. The close correlation between urinary metabolic ratios of the two drugs (rs = 0.91; P less than 0.001) demonstrates that the polymorphic N-oxidation of sparteine and 4-hydroxylation of debrisoquine are related pharmacogenetic entities; the metabolism of the two drugs is regulated by identical or closely related genetic factors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Debrisoquin / metabolism*
  • Female
  • Humans
  • Isoquinolines / metabolism*
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • Pharmacogenetics
  • Sparteine / metabolism*

Substances

  • Isoquinolines
  • Sparteine
  • Debrisoquin